- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04143646
New Technologies for Intensive Prevention Programs - NET-IPP (NET-IPP)
In a randomized trial patients hospitalized for myocardial infarction are prospectively enrolled and assigned to either a web-based intensive prevention program or usual care (1 : 1 randomization). The web-based program includes telemetric transmission of data on cardiocascular risk factors (physical activity, blood pressure, body weight) by patients to the study center, e-learning modules by the study center and repetitive electronic contacts by e-mails and apps between a prevention assistant and the patient.
In addition, genetic risk on cardiovascular events will be assessed in all patients of the intervention group by a polygenetic risk score (PRS). Patients of the intervention group are randomly assigned to disclosure of genetic risk vs. no disclosure. The study hypothesis is that disclosure of genetic risk improves cardiovascular risk factor control by increased patient motivation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Harm Wienbergen, M.D.
- Phone Number: +49-421-879-1430
- Email: harm.wienbergen@klinikum-bremen-ldw.de
Study Locations
-
-
-
Bremen, Germany, 28277
- Recruiting
- Herzzentrum Bremen
-
Contact:
- Harm Wienbergen, M.D.
- Phone Number: +49-421-879-1430
- Email: harm.wienbergen@klinikum-bremen-ldw.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalization due to acute myocardial infarction (ST-elevation or non-ST-elevation myocardial infarction) defined according to valid international guidelines
- Access to internet and consent to participate in a web-based prevention program
- Consent for genetic risk assessment for cardiovascular events and risk disclosure according to randomization
Exclusion Criteria:
- Patient refusal or inability to give informed consent
- Hemodynamically significant valvular heart disease
- Exercise limitations due to clinical conditions not related to CAD (such as severe orthopedic disorders,..)
- Any major non-cardiac condition that would adversely affect survival during the duration of the study (such as cancer with prognosis < 2 years,..)
- Inability to cooperate with the protocol, including longterm follow-up
- Chronic drug and alcohol abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Web-based prevention program
Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts. In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure. |
Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls. In a substudy evaluation of disclosure of genetic risk. |
No Intervention: Usual Care
Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of participants with serious adverse cardiovascular events
Time Frame: 24 months
|
Serious adverse cardiovascular events are death (total and cardiovascular), resuscitations, strokes, myocardial infarctions, coronary revascularizations or hospitalizations due to unstable angina.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL cholesterol
Time Frame: 24 months
|
LDL cholesterol levels in mg per dl
|
24 months
|
Smoking status
Time Frame: 24 months
|
Rate of participants who are active smokers in %
|
24 months
|
Physical inactivity
Time Frame: 24 months
|
Caloric expenditure as assessed by IPAQ (International Physical Activity Questionnaire) in kilocalories per week
|
24 months
|
Blood pressure
Time Frame: 24 months
|
Systolic and diastolic blood pressure measured in mmHg
|
24 months
|
Body mass index
Time Frame: 24 months
|
Body mass index in kg/m² (calculated from body weight and height)
|
24 months
|
HbA1c
Time Frame: 24 months
|
HbA1c levels in %
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to preventive medication
Time Frame: 24 months
|
Rate of patients with lipid-lowering medication, antiplatelets (= aspirine, ticagrelor, prasugrel, clopidogrel)
|
24 months
|
Assessment of quality of life
Time Frame: 24 months
|
Point score of the European Quality of Life 5 Dimensions (EQ5D) Questionnaire - Visual Analogue Scale (VAS).
The Scale ranges from 0 to 100, with 100 indicating the best Quality of Life and 0 indicating the worst Quality of Life
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIHKF 3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Web-based prevention program
-
Istanbul University - Cerrahpasa (IUC)Not yet recruiting
-
UnitedHealth GroupComcast Corporation; Dr. Ron AckermannCompleted
-
National Development and Research Institutes, Inc.National Institute on Drug Abuse (NIDA)UnknownHIV Infections | Hepatitis | Sexually Transmitted InfectionsUnited States
-
Queen's University, BelfastAXA PPP HealthcareCompleted
-
University of North Carolina, Chapel HillRTI InternationalCompletedObesity | Overweight
-
Kessler FoundationRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Saglik Bilimleri UniversitesiCompletedQuality of Life | Training | Self Efficacy | MothersTurkey
-
Gazi UniversityNot yet recruitingEvaluation of Effectiveness of the Web-Based Monitoring Program Given to Mothers of Premature BabiesGrowth | Infant Development | Maternal Stress
-
Taipei Medical UniversityCompletedBreast Feeding | Self Efficacy | Feeding BehaviorIndonesia
-
McGill UniversityCanadian Institutes of Health Research (CIHR)CompletedIncreased Risk for Cardiovascular DiseaseCanada